Harmonized outcome measures for use in atrial fibrillation patient registries and clinical practice: Endorsed by the Heart Rhythm Society Board of Trustees.

[1]  D. Singer,et al.  Association of of Atrial Fibrillation Clinical Phenotypes With Treatment Patterns and Outcomes: A Multicenter Registry Study , 2017, JAMA cardiology.

[2]  M. Chung,et al.  2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation , 2017, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[3]  Charles R Kerr,et al.  Progression of paroxysmal to persistent atrial fibrillation: 10-year follow-up in the Canadian Registry of Atrial Fibrillation. , 2017, Heart rhythm.

[4]  Randall J. Lee,et al.  Percutaneous left atrial appendage occlusion: the Munich consensus document on definitions, endpoints and data collection requirements for clinical studies. , 2016, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

[5]  Eric E. Smith,et al.  2014 ACC/AHA Key Data Elements and Definitions for Cardiovascular Endpoint Events in Clinical Trials , 2015, Journal of Nuclear Cardiology.

[6]  Eric E. Smith,et al.  2014 ACC/AHA Key Data Elements and Definitions for Cardiovascular Endpoint Events in Clinical Trials: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Data Standards (Writing Committee to Develop Cardiovascular Endpoints Data Standards). , 2015, Circulation.

[7]  Mark D. Huffman,et al.  AHA Statistical Update Heart Disease and Stroke Statistics — 2012 Update A Report From the American Heart Association WRITING GROUP MEMBERS , 2010 .

[8]  M. Ezekowitz,et al.  2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society. , 2014, Circulation.

[9]  Michelle B. Leavy,et al.  A framework for creating standardized outcome measures for patient registries. , 2014, Journal of comparative effectiveness research.

[10]  G. Fonarow,et al.  Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II: rationale and design of the ORBIT-AF II registry. , 2014, American heart journal.

[11]  G. Lip,et al.  Design and rationale of Global Registry on Long-Term Oral Antithrombotic Treatment in Patients with Atrial Fibrillation: a global registry program on long-term oral antithrombotic treatment in patients with atrial fibrillation. , 2014, American heart journal.

[12]  C. Murray,et al.  Worldwide Epidemiology of Atrial Fibrillation: A Global Burden of Disease 2010 Study , 2014, Circulation.

[13]  D. Singer,et al.  Estimates of current and future incidence and prevalence of atrial fibrillation in the U.S. adult population. , 2013, The American journal of cardiology.

[14]  D. Levy,et al.  Atrial Fibrillation Patterns and Risks of Subsequent Stroke, Heart Failure, or Death in the Community , 2013, Journal of the American Heart Association.

[15]  A. Ha,et al.  Health-related quality of life questionnaires: an important method to evaluate patient outcomes in atrial fibrillation ablation , 2013, Journal of Interventional Cardiac Electrophysiology.

[16]  M. Mack,et al.  Updated standardized endpoint definitions for transcatheter aortic valve implantation: the Valve Academic Research Consortium-2 consensus document. , 2012, The Journal of thoracic and cardiovascular surgery.

[17]  Jeroen J. Bax,et al.  Third universal definition of myocardial infarction. , 2012, Global heart.

[18]  W. Baine,et al.  The Agency for Healthcare Research and Quality , 2006, Italian Journal of Public Health.

[19]  D. Altman,et al.  The COMET (Core Outcome Measures in Effectiveness Trials) Initiative , 2011, Trials.

[20]  B. Gersh,et al.  Outcomes registry for better informed treatment of atrial fibrillation: rationale and design of ORBIT-AF. , 2011, American heart journal.

[21]  Marco Valgimigli,et al.  Standardized Bleeding Definitions for Cardiovascular Clinical Trials: A Consensus Report From the Bleeding Academic Research Consortium , 2011, Circulation.

[22]  John Spertus,et al.  Development and Validation of the Atrial Fibrillation Effect on QualiTy-of-Life (AFEQT) Questionnaire in Patients With Atrial Fibrillation , 2011, Circulation. Arrhythmia and electrophysiology.

[23]  N. Dreyer,et al.  Registries for Evaluating Patient Outcomes: A User’s Guide , 2010 .

[24]  D Bergqvist,et al.  Definition of major bleeding in clinical investigations of antihemostatic medicinal products in surgical patients , 2010, Journal of thrombosis and haemostasis : JTH.

[25]  S. Schulman,et al.  Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non‐surgical patients , 2005, Journal of thrombosis and haemostasis : JTH.

[26]  T. Bunch,et al.  Atrial fibrillation and dementia. , 2015, Trends in cardiovascular medicine.

[27]  G. Lip,et al.  International longitudinal registry of patients with atrial fibrillation at risk of stroke: Global Anticoagulant Registry in the FIELD (GARFIELD). , 2012, American heart journal.

[28]  L. Brooke.  The National Library of Medicine. , 1980, Hospital libraries.